Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Pressure is still on the pharma sector, says Mizuho's Jared Holz
07:23pm, Thursday, 08'th May 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
11:00am, Thursday, 08'th May 2025
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Lif
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as
Here's Why Amgen (AMGN) is a Strong Growth Stock
10:51am, Wednesday, 07'th May 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Amgen (AMGN) is a Strong Value Stock
10:46am, Tuesday, 06'th May 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen: Waiting Patiently For A Real Catalyst
08:00am, Tuesday, 06'th May 2025
Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, bu
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
10:00am, Monday, 05'th May 2025
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth
09:05am, Monday, 05'th May 2025
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
10:30am, Sunday, 04'th May 2025
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends,
Dogs Of The Dow Chase May's 'Safer' Buy
09:46am, Saturday, 03'rd May 2025
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou
Committee Movers: Eaton Corp PLC, Blackstone, Amgen, EOG Resources, Chevron and Exxon Mobile
01:47pm, Friday, 02'nd May 2025
Watch as the Investment Committee breaks down the latest market movers and shakers.
Landmark Science Makes RWE Services for Biopharma Industry a Boutique Experience
10:04am, Friday, 02'nd May 2025
LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evid
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
08:50am, Friday, 02'nd May 2025
AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
07:02am, Friday, 02'nd May 2025
In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those
Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript
08:42pm, Thursday, 01'st May 2025
Amgen Inc. (NASDAQ:AMGN ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Comm
